Treatment with the JAK3 inhibitor tofacitinib in combination with conventional chemotherapeutics is significantly more effective than monotherapy in a JAK3 mutant T-ALL mouse model [33]. Here, JAK3 is linked to acute lymphoblastic leukemia.